A complex interplay of factors contributes to thrombotic events and increased mortality rates in individuals with PV, including advanced age, previous thrombotic events, elevated hematocrit, increased allele burden of the JAK2 V617F driver mutation, and cardiovascular risk factors [31,32]. Here, JAK2 is linked to acquired polycythemia vera.